Literature DB >> 15265264

Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component.

Ramón Cacabelos1, Lucía Fernández-Novoa, Lola Corzo, Luís Amado, Victor Pichel, Valter Lombardi, Yasuhiko Kubota.   

Abstract

Alzheimer's disease (AD) and dementia with vascular component (DVC) are the most prevalent forms of dementia. Both clinical entities share many similarities, but they differ in major phenotypic and genotypic profiles as revealed by structural and functional genomics studies. Comparative phenotypic studies have identified significant differences in 25% of more than 100 parametric variables, including anthropometry, cardiovascular function, aortic atherosclerosis, brain atrophy, blood pressure, blood biochemistry, hematology, thyroid function, folate and vitamin B12 levels, brain hemodynamics and lymphocyte markers. The phenotypic profile of patients with DVC differs from that of AD patients in the following: anthropometric values (weight, height); cardiovascular function (ECG, heart rate); blood pressure; lipid metabolism (HDL-CHO, TGs); uric acid metabolism; peripheral calcium homeostasis; liver function (GOT, GPT, GGT); alkaline phosphatase; lactate dehydrogenase; red and white blood cells; regional brain atrophy (left temporal region, inter-hippocampal distance); and left anterior blood flow velocity. Functional genomics studies incorporating APOE-related changes in biological markers extended the difference between AD and DVC up to 57%. Brain perfusion studies show a severe brain hypoperfusion in dementia associated with enlarged age-dependent arterial perfusion times. Structural genomics studies with AD-related genes, including APP, MAPT, APOE, PS1, PS2, A2M, ACE, AGT, cFOS and PRNP genes, demonstrate different genetic profiles in AD and DVC, with an absolute genetic variation rate ranging from 30% to 80%, depending upon genes and genetic clusters. Single gene analysis identifies relative genetic variations ranging from 0% to 5%. The relative polymorphic variation in genetic clusters integrated by two, three or four genes associated with AD ranges from 1% to 3%. The main phenotypic differences between AD and DVC are genotype-dependent, especially in AD, probably indicating that different genomic factors are determinant for the expression of dementia symptoms which might be accelerated or induced by environmental and/or cerebrovascular factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265264     DOI: 10.1179/016164104225017677

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  8 in total

Review 1.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

2.  Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function.

Authors:  Katherine Ab Kellett; Jonathan Williams; Emma Rlc Vardy; A David Smith; Nigel M Hooper
Journal:  Int J Mol Epidemiol Genet       Date:  2011-02-10

3.  Serum alkaline phosphatase is elevated and inversely correlated with cognitive functions in subjective cognitive decline: results from the ReGAl 2.0 project.

Authors:  Virginia Boccardi; Valentina Bubba; Ilenia Murasecco; Martina Pigliautile; Roberto Monastero; Roberta Cecchetti; Michela Scamosci; Patrizia Bastiani; Patrizia Mecocci
Journal:  Aging Clin Exp Res       Date:  2020-05-03       Impact factor: 3.636

4.  Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: relevance to age-related neurodegeneration.

Authors:  Flaubert Tchantchou; Michael Graves; Daniela Ortiz; Eugene Rogers; Thomas B Shea
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

5.  Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.

Authors:  Ramón Cacabelos; Rocío Martínez; Lucía Fernández-Novoa; Juan C Carril; Valter Lombardi; Iván Carrera; Lola Corzo; Iván Tellado; Jerzy Leszek; Adam McKay; Masatoshi Takeda
Journal:  Int J Alzheimers Dis       Date:  2012-03-14

Review 6.  Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.

Authors:  Ramón Cacabelos; Arun Meyyazhagan; Juan C Carril; Pablo Cacabelos; Óscar Teijido
Journal:  J Pers Med       Date:  2018-01-03

7.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 8.  Personalized Management and Treatment of Alzheimer's Disease.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Life (Basel)       Date:  2022-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.